Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding
Island Pharma expands antiviral pipeline with Burnet Institute; NHMRC grant of over $780k to back ISLA-101, accelerating Galidesivir MVD program.
Latest Stories
Archer Materials is Building a Scalable Path to Commercial Quantum Technology
Archer Materials (ASX: AXE) charts a scalable, semiconductor-ready path to commercial quantum tech with the 12CQ project, targeting a 2026 qubit.
Island Pharma Partners with USAMRIID and Geneva Foundation for Galidesivir under FDA Animal Rule
Island Pharma signs a 3-year CRADA with USAMRIID and Geneva Foundation to fast-track Galidesivir for Marburg under FDA Animal Rule, eyeing NDA.
Bioxyne Boosts FY26 Outlook on Strong Performance and International Growth
Bioxyne lifts FY26 EBITDA guidance to AUD16.5-19m after record H1 FY2026 with AUD31.3m revenue (+149% YoY); expands capacity, enters UK/Germany/LATAM.
Radiopharm Theranostics Doses First Patient in RV-01 Phase 1/2a Trial for Aggressive Cancers
RAD doses first patient in RV-01 Phase 1/2a trial for aggressive cancers, a 177Lu-radiotherapeutic targeting B7-H3, to define dose for future studies.
Lumos Diagnostics Achieves BARDA Paediatric Study Milestone, Secures US$720k Payment
Lumos Diagnostics hits BARDA Milestone 6, secures US$720k non-dilutive payment as FebriDx paediatric study advances toward FDA submission and wider US TAM.
Little Green Pharma to Divest WA Production Site in $7.8 Million Sale and Lease-Back Deal
LGP to sell WA production site for $7.8m in a sale-and-lease-back to fund Australian and European expansion; settlement targeted mid-March 2026.
Cyclopharm Secures NIH Approval for Technegas, Boosting US Expansion
Cyclopharm wins NIH approval for Technegas, secures US purchase order; installation under FSS imminent as funding targets 250-300 US installs by H2 2026.
IDT Australia Reports Operational Improvements with New Leadership Team and Realignment Strategy
IDT Australia (ASX: IDT) reports improving six-month ops under a new leadership team and realignment strategy; revenue up 20% to $8.4m, EBITDA losses narrowed.
Cleo Diagnostics Selects Next-Generation Ella Platform to Deliver Ovarian Cancer Blood Test
Cleo Diagnostics (ASX:COV) selects Bio-Techne's Ella ELISA platform to run its ovarian cancer test, advancing toward FDA 510(k) filing and supply deal.
Botanix Pharmaceuticals Secures A$45 Million Capital Raise to Fund API Purchases and Supply Chain Diversification
Botanix secures A$45m to buy APIs and diversify supply; new shares A$0.06 at 45.5% discount; Sofdra posts Q2 FY26 A$9.1m revenue, 24% QoQ rise.
Rhythm Biosciences Secures Major Distribution Deal for ColoSTAT with 4Cyte Pathology
Rhythm Biosciences (ASX: RHY) has signed a significant non-exclusive distribution agreement with 4Cyte Pathology for its ColoSTAT test.